Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Hiroaki Nishimatsu is active.

Publication


Featured researches published by Hiroaki Nishimatsu.


Urologic Oncology-seminars and Original Investigations | 2017

Nomogram for predicting survival of postcystectomy recurrent urothelial carcinoma of the bladder

Tohru Nakagawa; Satoru Taguchi; Yukari Uemura; Atsushi Kanatani; Masaomi Ikeda; Akihiko Matsumoto; Kanae Yoshida; Taketo Kawai; Masayoshi Nagata; Daisuke Yamada; Yoshimitsu Komemushi; Motofumi Suzuki; Yutaka Enomoto; Hiroaki Nishimatsu; Akira Ishikawa; Yasushi Nagase; Yasushi Kondo; Yoshinori Tanaka; Toshikazu Okaneya; Yoshikazu Hirano; Mitsuru Shinohara; Hideyo Miyazaki; Tetsuya Fujimura; Hiroshi Fukuhara; Haruki Kume; Yasuhiko Igawa; Yukio Homma

PURPOSE We aimed to identify prognostic clinicopathological factors and to create a nomogram able to predict overall survival (OS) in recurrent urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC). MATERIALS AND METHODS Among 1,087 patients with UCB who had undergone RC at our 11 institutions between 1990 and 2010, 306 patients who subsequently developed distant metastasis or local recurrence or both were identified. Clinical data were collected with medical record review. Univariate and multivariate Cox regression models addressed OS after recurrence. A nomogram predicting postrecurrence OS was constructed based on Cox proportional hazards model, without using postrecurrence factors (systemic chemotherapy and resection of metastasis). The performance of the nomogram was internally validated by assessing concordance index and calibration plots. RESULTS Of the 306 patients, 268 died during follow-up with a median survival of 7 months (95% CI: 5.8-8.5). Postrecurrence chemotherapy was administered in 119 patients (38.9%). Multivariable analysis identified 9 independent predictors for OS; period of time from RC to recurrence (time-to-recurrence), symptomatic recurrence, liver metastasis, hemoglobin level, serum alkaline phosphatase level, serum lactate dehydrogenase level, serum C-reactive protein level, postrecurrence chemotherapy, and resection of metastasis. A nomogram was formed with the following 5 variables to predict OS: time-to-recurrence, symptomatic recurrence, liver metastasis, albumin level, and alkaline phosphatase level. Concordance index rate was 0.75 (95% CI: 0.72-0.78) by internal validation using Bootstraps with 1,000 resamples. Calibration plots showed that the nomogram fitted well. CONCLUSIONS We identified 9 clinicopathological factors as independent OS predictors in postcystectomy recurrence of UCB. We also created a validated nomogram with 5 variables that efficiently stratified those patients regardless of eligibility for chemotherapy. The nomogram would be useful for acquiring relevant prognostic information and for stratifying patients for clinical trials.


World Journal of Surgical Oncology | 2014

Multiple primary malignant neoplasms of the glottis, renal pelvis, urinary bladder, oral floor, prostate, and esophagus in a Japanese male patient: a case report.

Yoshihiro Mukaiyama; Motofumi Suzuki; Teppei Morikawa; Yoshiyuki Mori; Yuta Takeshima; Tetsuya Fujimura; Hiroshi Fukuhara; Tohru Nakagawa; Hiroaki Nishimatsu; Haruki Kume; Yukio Homma

Owing to recent advances in diagnostic and surgical techniques for cancer, a patient diagnosed with two or more neoplasms is not rare. We report on the case of a 58-year-old male with multiple primary malignant neoplasms, who suffered from three histological types of malignant neoplasm in six organs, namely the glottis, renal pelvis, urinary bladder, oral floor, prostate, and esophagus in chronological order. The first neoplasm was a squamous cell carcinoma of the glottis diagnosed in 2006. The second and third neoplasms were urothelial carcinomas of the right renal pelvis and urinary bladder, respectively, diagnosed in 2008. The remaining three neoplasms were diagnosed in 2010, namely a squamous cell carcinoma of the oral floor, an adenocarcinoma of the prostate, and a squamous cell carcinoma of the esophagus. The glottic cancer and esophageal cancer were treated by external radiation therapy. The malignant neoplasms of the oral floor and those which originated in the urinary tract were surgically resected. All neoplasms except the malignant neoplasm of the oral floor were well controlled. The patient died of cervical lymph node metastasis from the squamous cell carcinoma of the oral floor in January 2011. As far as we know, the present report is the first one on this combination of primary malignant neoplasms.


International Journal of Urology | 2018

Chronological changes in the epidemiological characteristics of upper urinary tract urolithiasis in Japan

Shinichi Sakamoto; Katsuhito Miyazawa; Takahiro Yasui; Taro Iguchi; Misuzu Fujita; Hiroaki Nishimatsu; Takuro Masaki; Toru Hasegawa; Hatsuki Hibi; Takashi Arakawa; Ryosuke Ando; Yoshinari Kato; Noritaka Ishito; Satoshi Yamaguchi; Ryoji Takazawa; Masao Tsujihata; Koichiro Akakura; Akira Hata; Tomohiko Ichikawa

To assess epidemiological and chronological trends of upper urinary tract stones in Japan in 2015.


Cancer Research | 2016

Abstract 94: Genomic landscape and clonal expansions of upper urinary tract urothelial carcinoma

Yoichi Fujii; Yusuke Sato; Shigekatsu Maekawa; Hiromichi Suzuki; Tetsuichi Yoshizato; Kenichi Yoshida; Yuichi Shiraishi; Kenichi Chiba; Hiroko Tanaka; Tohru Nakagawa; Haruki Kume; Hiroaki Nishimatsu; Yoshikazu Hirano; Masashi Sanada; Hideki Makishima; Satoru Miyano; Yukio Homma; Seishi Ogawa

Backgrounds Upper urinary tract urothelial carcinoma (UUTUC) is a relatively rare and poor prognostic cancer which accounts for 5-10% of all urothelial malignancies. Despite the histological similarity, there are epidemiological and clinical differences between UUTUC and bladder urothelial carcinoma (BUC). Compared to BUC, the molecular pathogenesis of UUTUC is poorly understood. Urothelial carcinoma is also characterized by frequent multifocal lesions, suggesting field effects from mutagenic agents in urine and/or a dissemination from the primary tumor. To reveal the origin of the multifocality as well as the molecular pathogenesis of UUTUC, we performed comprehensive molecular analysis of UUTUC with regional multiple sampling. Materials & methods Surgical specimens of UUTUC and matched normal samples were obtained from 57 patients with various stages who underwent nephroureterectomy. Morphologically normal urothelial epithelia were also obtained in 5 cases, all of which were confirmed to be pathologically intact by an expert pathologist. Genomic DNA was extracted from each specimen and was subjected to whole exome sequencing using Hiseq 2500 for the detection of both somatic mutations and copy number lesions. Results In copy number analysis, recurrent deletions in 8p, 9p and 9q were identified, where homo deletions of 9p21.3 (CDKN2A) were most frequent (40.7%) Focal amplifications in 11q13.3 (CCND1) and 12q15 (MDM2) were also found. On average, 230 somatic nonsynonymous mutations per sample were detected. The mutation signature was biased to age-related and APOBEC patterns. Mutations were most frequently observed in KMT2D (42% of cases), followed by TP53 (32%), FGFR3 (24%), KDM6A (24%), EP300 (21%) and CREBBP (13%), which were also reported to be significantly mutated in BUC. However, the frequencies of these genetic lesions were substantially different between UUTUC and BUC. For example, abnormalities in RB1, CDKN1A and PIK3CA were not detected or rare in UUTUC but have been reported to be common targets of genetic lesions in BUC. In the analysis of normal epithelia, an average of 12.7 somatic mutations per sample were found but with low variant allele frequencies between 0.05−0.1. Somatic mutations in adjacent epithelia and preoperative urine were frequently shared by primary tumor, supporting a possibility of tumor disseminations from the original sites through urinary flow. In contrast, in other cases, distant epithelia harbored driver gene mutations that were not shared by the primary tumors, suggesting the presence of a mutagenic field effect on urothelial carcinogenesis. Conclusions Despite the similarity in their mutation spectrum, UUTUC and BUC seemed to have distinct pathogenesis in terms of the difference in mutation frequencies. Our data suggested that both dissemination and field effect might contribute to multifocal occurrence of UUTUC. These findings will provide a new insight into the pathophysiology of UUTUC. Citation Format: Yoichi Fujii, Yusuke Sato, Shigekatsu Maekawa, Hiromichi Suzuki, Tetsuichi Yoshizato, Kenichi Yoshida, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Tohru Nakagawa, Haruki Kume, Hiroaki Nishimatsu, Yoshikazu Hirano, Masashi Sanada, Hideki Makishima, Satoru Miyano, Yukio Homma, Seishi Ogawa. Genomic landscape and clonal expansions of upper urinary tract urothelial carcinoma. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 94.


World Journal of Urology | 2017

Prognostic significance of serum neuron-specific enolase in small cell carcinoma of the urinary bladder

Akihiro Naito; Satoru Taguchi; Tohru Nakagawa; Akihiko Matsumoto; Yasushi Nagase; Mariko Tabata; Jimpei Miyakawa; Motofumi Suzuki; Hiroaki Nishimatsu; Yutaka Enomoto; Shintaro Takahashi; Toshikazu Okaneya; Daisuke Yamada; Takamitsu Tachikawa; Shigeru Minowada; Tetsuya Fujimura; Hiroshi Fukuhara; Haruki Kume; Yukio Homma


World Journal of Urology | 2017

Efficacy of post-nephroureterectomy cisplatin-based adjuvant chemotherapy for locally advanced upper tract urothelial carcinoma: a multi-institutional retrospective study

Tohru Nakagawa; Yoshimitsu Komemushi; Taketo Kawai; Masafumi Otsuka; Jimpei Miyakawa; Yukari Uemura; Atsushi Kanatani; Satoru Taguchi; Akihiro Naito; Motofumi Suzuki; Hiroaki Nishimatsu; Yoshikazu Hirano; Yoshinori Tanaka; Akihiko Matsumoto; Hideyo Miyazaki; Tetsuya Fujimura; Hiroshi Fukuhara; Haruki Kume; Yasuhiko Igawa; Yukio Homma


Preventive Medicine and Community Health | 2018

A prospective randomized controlled study on the Suppression of Prostate Cancer by Naftopidil (SNAP)

Daisuke Yamada M.D.; Haruki Kume; Hideyo Miyazaki; Mototsugu Tanaka; Munenori Takata; Yukari Uemura; Teppei Morikawa; Yutaka Enomoto; Motofumi Suzuki; Hiroaki Nishimatsu; Tohru Nakagawa; Tetsuya Fujimura; Hiroshi Fukuhara; Yasuhiko Igawa; Yukio Homma


Circulation | 2018

Endogenous Interleukin-1β Is Implicated in Intraplaque Hemorrhage in Apolipoprotein E Gene Null Mice

Etsu Suzuki; Hiroyuki Imuta; Daishi Fujita; Masao Takahashi; Shigeyoshi Oba; Arihiro Kiyosue; Hiroaki Nishimatsu


ics.org | 2010

Oral administration of steroid for ulcer type interstitial cystitis

Yukio Homma; Akira Nomiya; Hiroaki Nishimatsu; Tetsuya Fujimura; Hiroshi Enomoto; Motofumi Suzuki; Hiroshi Fukuhara; Haruki Kume


ics.org | 2010

Dose urinary NGF level predict symptomatic severity in patients with interstitial cystitis

Yuzuri Tsurumaki; Akira Nomiya; Hiroaki Nishimatsu; Yutaka Enomoto; Tetsuya Fujimura; Hiroshi Fukuhara; Motofumi Suzuki; Haruki Kume; Yukio Homma

Collaboration


Dive into the Hiroaki Nishimatsu's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Yutaka Enomoto

Memorial Hospital of South Bend

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge